Anthracyclines

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 299-320

  Arcamone, Federico Maria ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUNDS; CHROMOPHORES; KETONES; METABOLITES; PLANTS (BOTANY); SYNTHESIS (CHEMICAL);

AEROBIC FERMENTATION; AROMATIC DERIVATIVES; IMMUNOSUPPRESSANTS; INTRAMOLECULAR REACTIONS; MICROBIAL METABOLITES; MOLECULAR DIVERSITY; POLYKETIDE SYNTHASES; STRUCTURAL GROUPS;

ANTIBIOTICS;

EID: 84886165633     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (112)

1. Brockmann, H., Anthracyclinone und anthracycline (Rhodomycinone, Pyrromycinone und Ihre Glycoside), in Forschritte der Chemie Organische Naturstoffe, Zechmeister, L, Ed., Springer, Vienna, 21, 121-182, 1963.
2. O’Hagan, D., The polyketide metabolites, Ellis Horwood, Chichester, 1991.
3. Arcamone, F. et al., Isolamento ed attività antitumorale di un antibiotico da Streptomyces sp., Giorn. Microbiol., 9, 83, 1961.
4. Arcamone, F., Doxorubicin anticancer antibiotics, De Stevens, G. Ed., Academic Press, New York, 1981.
5. Arcamone, F., The development of new antitumor anthracyclines, in Anticancer agents based on natural products models. Cassady, J. and Douros, J. Eds., Academic Press, New York, 1980, chapter 1.
6. Arcamone, F. and Penco, S., Synthesis of new doxorubicin analogs, in Anthracycline and anthracenedione-based anticancer agents, Lown, J.W. Ed., Elsevier, Amsterdam, 1988, chapter 1.
7. Weiss, R.B., The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19, 670, 1992.
8. Arcamone, F. et al., New developments in antitumor anthracyclines, Pharmacol. Ther. 76, 117, 1997.
9. Takeuchi, T. Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry. J. Cancer Res. Clin. Oncol., 121, 505, 1995.
10. Oki, T., Antitumor anthracycline antibiotics from microbial origin, in ref. (5), p.103.
11. Arcamone, F. and Cassinelli, G., Biosynthetic anthracyclines, Curr. Med. Chem. 5, 391, 1998.
12. Fujii, I. and Ebizuka, Y., Anthracycline biosynthesis in Streptomyces galilaeus, Chem. Rev., 97, 2511, 1997.
13. Hutchinson, C.R., Biosynthetic studies of daunorubicin and tetracenomycin C, Chem. Rev., 97, 2525, 1997.
14. Hopwood, D.A., Genetic contributions to understanding polyketide synthase, Chem. Rev., 97, 2465, 1997.
15. Di Marco, A. et al., Studi sperimentali sull’attività antineoplastica del nuovo antibiotico daunomicina, Tumori, 49, 203, 1963.
16. Arcamone, F. et al., Daunomycin. I. The structure of daunomycinone, J. Am. Chem. Soc., 86, 5334, 1964.
17. Arcamone, F. et al., Daunomycin. II. The structure and stereochemistry of daunosamine, J. Am. Chem. Soc., 86, 5335, 1964.
18. Arcamone, F. et al., The structure of daunomycin, Tetrahedron Lett., 30, 3349, 1968.
19. Arcamone, F. et al., The total absolute configuration of daunomycin, Tetrahedron Lett., 30, 3353, 1968-20.
20. Arcamone, F. et al., Struttura e stereochimica della daunomicina, Gazz. Chim. Ital., 100, 848, 1970.
21. Angiuli, R. et al., Structure of daunomycin; x-ray analysis of N-Br-acetyl-daunomycin solvate, Nat. New Biol., 234, 78, 1971.
22. Dubost, M. et al., Rubidomycin, a new antibiotic with cytostatic properties, Cancer Chemother. Rep., 41, 35, 1964.
23. Bernard, J. et al., Recent results in cancer research: rubidomycin, Springer, Berlin, 1969.
24. Arcamone, F. et al., Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng., 11, 1101, 1969.
25. Arcamone, F. et al., Adriamycin(14-hydroxydaunomycin), a novel antitumor antibiotic, Tetrahedron Lett., 13, 1007, 1969.
26. Di Marco, A., Gaetani, M. and Scarpinato, B.M., A new antibiotic with antitumor activity, Cancer Chemother. Rep., 53, 33, 1969.
27. Bonadonna, G. et al., Clinical evaluation of Adriamycin a new antitumor antibiotic, Brit. Med. J., 3, 503, 1969.
28. Carter, S.K., Adriamycin — a review, J. Nat. Cancer Inst., 55, 1265, 1975.
29. Borchmann, P. et al., Idarubicin: a brief overview on pharmacology and clinical use, Int. J. Clin. Pharmacol. Ther., 3, 80, 1997.
30. Wang, A.H.J., Intercalative drug binding to DNA, Curr. Opin. Struct. Biol., 2, 361, 1992.
31. Stutter, E., Schuetz, H. and Berg, H., Quantitative determination of cooperative anthracycline-DNA binding, ref. 5, p. 245.
32. Ughetto, G., X.-Ray diffraction analysis of anthracycline-oligonucleotide complexes, ref. 5, p. 296.
33. Pullman, B., Binding affinities and sequence selectivity in the interaction of antitumor anthracyclines and anthracenediones with double stranded polynucleotides and DNA, ref. 5, p. 371.
34. Chaires, J.B., Herrera, J.E., and Waring, J.M., Preferential binding of daunomycin to 5′ at CG and 5′ at GC sequences revealed by footprinting titration experiments, Biochemistry, 29, 6145, 1990.
35. Frederick, C.A. et al., The structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin, Biochemistry, 29, 2538, 1990.
36. Tewey, K.M. et al, Adriamycin induced DNA damage mediated by mammalian DNA topoisomerase II, Science, 226, 466, 1984.
37. Capranico, G. et al., Sequenze selective topoisomerase Ii inhibition by anthracycline derivatives in SV 40 DNA: relationship with DNA binding affinity and cytotoxicity, Biochemistry, 29, 562, 1990.
38. Capranico, G., Kohn, K.W. and Pommier, Y., Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin, Nucleic Acids Res., 22, 6611, 1990.
39. Zunino, F. and Capranico G., DNA topoisomerase II as the primary target of anti-tumor anthracyclines, Anticancer Drug Design, 4, 307, 1990.
40. Binaschi, M. et al., Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity, Mol. Pharmacol., 6, 1053, 1997.
41. Gerwitz, D.A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracyclines antibiotics Adriamycin and daunorubicin, Biochem. Pharmacol., 57, 727, 1992.
42. Pommier, Y., DNA topoisomerase II inhibitors, in Cancer therapeutics, experimental and clinical agents, Techter B.A. Ed., Humana Press, Totowa, NJ, 153, 1997.
43. Nielsen, D., Maare, C. and Skovsgaard, T., Cellular resistance to anthracyclines, Gen. Pharmacol., 27, 255, 1996.
44. Beaumont, P.O. et al., Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin, Cancer Res., 58, 947, 1998.
45. Gaudiano, G., Resing, K. and Koch, T.H., Reaction of reduced anthracyclines with glutathione — formation of aglycone conjugates, J. Am. Chem. Soc., 116, 6537, 1994.
46. Kim, R., The role of HER-2 oncoprotein in drug-sensitivity in breast cancer, Oncol. Rep., 9, 3, 2002.
47. Bellini, O. and Solcia, E., Early and late sarcoplasmic reticulum changes in doxorubicin cardiomyopathy, Virchows Arch. (Cell Pathol.), 49, 137, 1985.
48. Ishikawa, T. and Sies, H., Cardiac transport of glutathione disulfide and S-conjugates. Studies with isolated perfused rat heart during hydroperoxide metabolism, J. Biol. Chem., 239, 3838, 1984.
49. Olson, R.D. et al., Regulatory role of glutathione and soluble sulfidryl groups in the toxicity of Adriamycin, J. Pharmacol. Exp. Ther., 215, 450, 1980.
50. Formelli, F. et al., Effect of Adriamycin on DNA synthesis in mouse and rat heart, Cancer Res., 38, 3286, 1978.
51. Ellis, C.N., Ellis, M.B. and Blakemore, W.S., Effect of Adriamycin on heart mitochondrial DNA, Biochem. J., 245, 309, 1987.
52. Gatti, G. et al., Injectable stabilized solutions containing an antitumor anthracycline glucoside, BP 2178311 (Feb. 11, 1987), Chem. Abs. 107, 223275, 1997.
53. Gatti, G. et al., Ready to use injections containing anthracycline glycosides in acidic solution, Germ. Offen. 3741037 (Jun. 9, 1988), Chem. Abs. 110, 141560, 2000.
54. Suarato, A. et al., Anthracycline chemistry: direct conversion of daunorubicin into the L-arabino, Lribo, and L-lyxo analogues, and selecrive deoxygenation at C-4, Carbohydr. Res., 98, C1-C3, 1981.
55. Badalassi, F. et al., Efficient enantioselective synthesis of (R)-2-hydroxy-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalene, the key intermediate in the synthesis of anthracycline antibiotics, Tetrahedron Asymmetry, 12, 3155, 2001.
56. Cabri, W. et al., Process for preparing anthracyclinones, U.S. Patent 5,180,758 (Jan. 19, 1993).
57. Cacchi, S. et al., Palladium-catalyzed triethylammonium formate reduction of aryl triflates, a selective method for the deoxygenation of phenols, Tetrahedron Lett., 27, 5541, 1986.
58. Arcamone, F. and Penco, S., Chemical derivatives of anticancer antibiotics with different DNA binding properties, in Molecular mechanisms of carcinogenic and antitumor activity, Chagas, C. and Pullman B. Eds. Pontificiae Academiae Scientiarum Scripta Varia, Vatican City, 70, 225, 1987.
59. Arcamone, F. and Penco, S., Relationship of structure to anticancer activity and toxicity in anthracyclines, Gann Monogr. Cancer Res., 36, 81, 1989.
60. Capranico, G. et al., Role of DNA breakage to cytotoxicity of doxorubicin, 9-deoxydoxorubicin, and 4-demethyl-6-deoxydoxorubicin in murine leukemia P388 cells, Cancer Res., 49, 2022, 1989.
61. Pasqui, F. et al., Synthesis of ring A fluorinated anthracyclines, Tetrahedron, 52, 185, 1996.
62. Animati, F. et al., Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation, Mol. Pharmacol., 50, 603, 1996.
63. Berettoni, M. et al., Synthesis of 14-fluorodoxorubicin, Tetrahedron Lett., 43, 2867, 2002.
64. Ringenberg, Q.S. et al., Clinical cardiotoxicity of esorubicin (4-deoxydoxorubicin, DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report, Invest. New Drugs, 8, 221, 1990.
65. Barbieri, B. et al., Chemical and biological characterization of 4-iodo-4-deoxydoxorubicin, Cancer Res., 47, 4001, 1987.
66. Sessa, C. et al., Phase II studies of 4-iodo-4-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers, Ann. Oncol., 2, 727, 1991.
67. Merlini, G. et al., Interaction of the anthracycline 4-iodo-4-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis, Proc. Natl. Acad. Sci. U.S.A., 92, 2959, 1995.
68. Gertz, M.A. et al., A multicenter phase II trial of 4-iodo-4deoxydoxorubicin (IDOX) in primary amyloidosis (AL), Amyloid, 9, 24, 2002.
69. Priebe, W. et al., Non-cross-resistant anthracyclines with reduced basicity and increased stability of the glycosidic bond, in ACS symposium series 574: Anthracycline antibiotics, new analogues, methods of delivery, and mechanism of action, Priebe, W. Ed., American Chemical Society, Washington, DC, 1995.
70. Booser, D.J. et al., Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer, Cancer Chemother. Pharmacol., 50, 6, 2002.
71. Acton, M., Wasserman, K. and Newman, R.A., Morpholinyl anthracyclines, ref. 6, chapter 2.
72. Bakker, M. et al., Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non small cell lung cancer, renal cancer and other solid tumor patients, Br. J. Cancer, 77, 139, 1998.
73. Roaten, J.B., Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity. Mol. Cancer Therapeutics, 1, 483, 2002.
74. Boivin J., Monneret, C. and Pais, M., Approche de la synthèse d’anthracyclines oligosaccharidiques. Hemisynthèse de la 4-O-(2.deoxy-L-fucosyl)-daunorubicine, Tetrahedron, 37, 4219, 1981.
75. El Khadem, H.S. and Matsura, D., Synthesis of 7-(3-amino-2,3,6-trideoxy-4-O-(2,6 dideoxy-α-L-lyxohexopyranosyl)-α-L-lyxo-hexopyranosyl)-daunomycinone, Carbohydr. Res., 101, C1, 1982.
76. Horton, D. et al., Synthesis and antitumor activity of anthracycline disaccharide glycosides containing daunosamine, J. Antibiotics, 46, 1720, 1993.
77. Capranico, G. et al., Influence of structural modifications at the 3 and 4 positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome drug resistance, Mol. Pharmacol., 45, 908, 1994.
78. Capranico, G., Butelli, E. and Zunino, F., Change of sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerisation of the amino group of the sugar moiety, Cancer Res., 55, 312, 1995.
79. Animati, F. et al., New anthracycline disaccharides. Synthesis of L-daunosaminyl-α(1-4)-2-deoxy-Lrhamnosyl and of L-daunosaminyl-α(1-4)-2-deoxy-L-fucosyl daunorubicin analogues, J. Chem. Soc. Perkin Trans. I, 1327, 1996.
80. Arcamone, F. et al., Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides, Biochem. Pharmacol., 57, 1133, 1999.
81. Arcamone, F. et al., A doxorubicin disaccharide analog: apoptosis related improvement of efficacy in vivo, J. Natl. Cancer Inst., 89, 1217, 1997.
82. Pratesi, G. et al., Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts, Clin. Cancer Res., 4, 2833, 1998.
83. Pratesi, G. et al., A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue, Biochem. Pharmacol., 62, 63, 2001.
84. Cirillo, R. et al., Comparison of doxorubicin and MEN 10755-induced long term progressive cardiotoxicity in the rat, J. Cardiovasc. Pharmacol., 35, 100, 2000.
85. Messori, L. et al., Solution chemistry and DNA binding properties of MEN 10755, a novel disaccharide analogue of doxorubicin, Bioorg. Med. Chem., 9, 938, 2001.
86. Temperini, C. et al., The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes, Nucleic Acids Res., 31, 1464, 2003.
87. Garbesi, A. et al., Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives, Nucleic Acids Res., 25, 2121, 1997.
88. Capobianco, M.L. et al., New TFO conjugates containing a carminomycinone derived chromophore, J. Bioconjugate Chem., 12, 523, 2001.
89. Catapano C. et al., Synthesis of daunomycin conjugated triple-forming oligonucleotides that act as selective repressors of c-myc gene expression, in Proc. 92nd Annual Meeting Am. Ass. Cancer Res., Abstract 4563, New Orleans LA, 2001.
90. Young, R..C., Ozols, R.F., and Myers, C.E., Medical progress. The anthracycline antineoplastic drugs, New Engl. J. Med., 305, 149, 1981.
91. Geffen, D.B. and Man, S., New drugs for the treatment of cancer, 1990-2001, Isr. Med. Assoc. J., 4, 1124, 2002.
92. Hoelzer, D. and Gale, R.P., Acute lymphoblastic leukemia in adults: recent progress, future directions, Semin. Hematol., 24, 27, 1987.
93. Gale, R.P. and Foon, K.A., Therapy of acute myelogenous leukaemia, Semin. Hematol., 24, 40, 1987.
94. Bonadonna, G., Principi di chemioterapia antitumorale, in Manuale di Oncologia Medica, Bonadonna, G. and Robustelli della Cuna, G. Eds., Masson Italia, Milan, 1981, chap. 18.
95. Beretta, G., Cancer chemotherapy regimens, Farmitalia-Carlo Erba SpA, Milan, 1983.
96. Robert, J. and Gianni, L., Pharmacokinetics and metabolism of anthracyclines, Cancer Surv., 17, 219, 1993.
97. Gill, P. et al., Time dependency of Adriamycin and adriamycinol kinetics, Cancer Chemother. Pharmacol., 10, 120, 1983.
98. Ganzina, F., 4′-Epidoxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data, Cancer Treat Rev., 10, 1, 1983.
99. Mouridsen, H.T. et al., Current status of epirubicin (Farmorubicin) in the treatment of solid tumours, Acta Oncol., 29, 257, 1990.
100. Plosker, G.L. and Fauld, D., Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy, Drugs, 45, 788, 1993.
101. Robert, J., Clinical pharmacokinetics of epirubicin, Clin Pharmacokinet., 26, 428, 1994.
102. Cersosimo, R.J., Idarubicin: an anthracycline antineoplastic agent, Clin. Pharm., 11, 152, 1992.
103. Buckley, M.M. and Lamb, H.M., Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer, Drugs Aging, 11, 61, 1997.
104. Warrell Jr., R.P., Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers, Drugs Exp. Clin. Res., 12, 275, 1986.
105. Schrivers, D. et al., Phase I study of MEN-10755, a new anthracycline in patients with solid tumors: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group, Ann. Oncol., 13, 385, 2002.
106. Bos, A.M.E. et al., Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours, Cancer Chemother. Pharmacol., 48, 361, 2001.
107. Caponigro, F. et al., A phase II study of MEN 10755 in patients with advanced or metastatic ovarian cancer. EORTC-NCI-AACR Meeting, (Abstr. 42), Eur. J. Cancer, 38 (Suppl. 7) S18, 2002.
108. Tjan-Heijnen, V.C.G. et al., A phase II study with MEN 10755 as second line therapy in advanced non small cell lung cancer (NSCLC), 27th ESMO Congress, Nice, France, Oct. 2002. Abstr. 542P, Ann. Oncol., 13, 55, 2002.
109. Comandini, A. et al., MEN 10755 in lung cancers: a survey of phase II studies in patients with advanced or metastatic NSCLC and SCLC-ED. 24th Winter Meeting of the EORTC-PAMM Group, Florence, Italy, Feb. 5-8, 2003.
110. Muggia, F.M., Liposomal encapsulated anthracyclines: new therapeutic horizons, Curr Oncol Rep., 3, 156, 2001.
111. Gabizon, A., Shmeeda, H. and Barenholz, Y., Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies, Clin Pharmacokinet., 42, 419, 2003.
112. Perez, A.T et al., Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc. experience, Cancer Invest., 20 (Suppl. 2), 22, 2002.